首页> 外文期刊>Veterinary World >Production, immunogenicity, stability, and safety of a vaccine against Clostridium perfringens beta toxins
【24h】

Production, immunogenicity, stability, and safety of a vaccine against Clostridium perfringens beta toxins

机译:疫苗对蛋白质的生产,免疫原性,稳定性和安全性强制β毒素

获取原文
       

摘要

Background and Aim: The beta toxin is causing the most severe Clostridium perfringens -related diseases. This work was dedicated to developing a vaccine against beta toxin using C. perfringens type C (NCTC 3180). Materials and Methods: The crude toxoid harvest contained 710 limits of flocculation (Lf)/mL. The vaccine was formulated. Each 1 mL of the final vaccine product contained at least 50 Lf/mL of beta toxoids, 0.2 mL 3% aluminum hydroxide gel (equivalent to 5.18 mg of aluminum), 0.001% W/V thiomersal, formaldehyde 0.05% W/V, and ~0.7 mL phosphate-buffered saline (pH 7.2). The efficacy of the vaccine was evaluated by potency, stability, and safety tests. Results: The vaccine demonstrated 24.36 IU/mL (standard deviation, ±0.56) and 14.74 IU/mL (±0.36) of neutralizing antibodies in rabbits and cattle, respectively. Indeed, these levels were above the minimum recommended by international protocols since the obtained antibody levels had 2.43- and 1.47-fold increase in both rabbits and cattle, respectively, over the minimum antitoxin level suggested by the United States Department of Agriculture. Interestingly, our formulation was capable of inducing 1.65-fold higher immune responses in rabbits than that stimulated in cattle (65% increase) with a significant difference (p0.0001). The vaccine was stable up to 30 months. The vaccinated rabbits were suffered from a temporarily slight increase in temperatures in the first 10 h without any significant difference (p0.05). Conclusion: The research showed a procedure for the manufacturing process of the vaccine against C. perfringens beta toxins with a feasible quantity and the vaccine described here showed to be effective in eliciting levels of neutralizing antibodies higher than required by international standards. In addition, The vaccine was stable up to 30 months. Thus, it may represent an effective and safe for preventing C. perfringens -related diseases in rabbits and cattle, although further studies to prove its efficacy in the field on other farm animals are still needed.
机译:背景和目的:β毒素导致最严重的梭菌患者的疾病。这项工作致力于使用C.流水型C(NCTC 3180)开发针对β毒素的疫苗。材料和方法:粗毒素收获含有710次絮凝(LF)/ mL。配制疫苗。每种1ml最终疫苗产物含有至少50μl/ ml的β毒素,0.2ml 3%氢氧化铝凝胶(相当于5.18mg铝),<0.001%w / v巯基,甲醛<0.05%w / v ,〜0.7mL磷酸盐缓冲盐水(pH7.2)。通过效力,稳定性和安全测试评估疫苗的疗效。结果:疫苗分别展示了24.36 IU / mL(标准差,±0.56)和14.74IU / mL(±0.36)分别中和兔和牛的中和抗体。实际上,这些水平高于国际方案推荐的最低限度,因为在美国农业部建议的最低抗毒素水平上,所获得的抗体水平分别具有2.43倍和1.47倍的增加。有趣的是,我们的配方能够在兔子中诱导1.65倍的免疫应答,而不是牛(65%增加),具有显着差异(P <0.0001)。疫苗长达30个月。疫苗接种的兔子在前10小时的温度下暂时略微增加,没有任何显着差异(p> 0.05)。结论:该研究表明,对C.疫苗的制造过程的过程,其具有可行量的完全β毒素,并且这里描述的疫苗显示出于高于国际标准所需的中和抗体的引发水平。此外,疫苗稳定达30个月。因此,它可以代表预防兔和牛中的完全和安全的疾病的有效和安全,尽管仍然需要进一步的研究,以证明其在其他农场动物的田间中的功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号